Sign in

Private company

Athenex, Inc.

American pharmaceutical preparations company based in Buffalo2

In its 2023 annual report the company says: “Athenex, Inc., together with its subsidiaries, is a clinical-stage biopharmaceutical company dedicated to becoming a leader in the discovery, development and commercialization of next-generation products for the treatment of cancer. We are focused on our innovative cell therapy platform, based on natural killer T cells.”60

Last updated Oct 21, 2026.

Overview

  • IndustryPharmaceutical Preparations2
  • HeadquartersBuffalo, United States2
  • Incorporated inDE3
  • Business address1001 Main Street, Suite 600, Buffalo, Ny 142033
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI5493001V4L0Q5EPPOH522
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 37233852

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

26.0%Gross margin4
-68.1%Operating margin4
-100.6%Net margin4
7.8%Revenue growth, 20224

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Cost of revenue38¢$76.1M
  • Research and development26¢$51.8M
  • Selling, general and admin23¢$44.9M
  • Interest13¢$25.8M
  • Income tax0¢$347.0K

Out of $102.8M in revenue.4 The company lost money this year.

Financial statements

Revenue56784$102.8M in 2022+400% since 2016
0$50.0M$100.0M$150.0M2016: $20.6M$20.6M20162017: $38.0M$38.0M2017+85%2018: $89.1M$89.1M2018+134%2019: $101.2M$101.2M2019+14%2020: $144.4M$144.4M2020+43%2021: $95.4M$95.4M2021−34%2022: $102.8M$102.8M2022+8%
Gross profit784$26.7M in 2022−37% since 2018
0$20.0M$40.0M$60.0M2018: $42.1M$42.1M20182019: $31.6M$31.6M2019−25%2020: $49.0M$49.0M2020+55%2021: $32.5M$32.5M2021−34%2022: $26.7M$26.7M2022−18%
Operating income56784-$70.0M in 2022−18% since 2016
-$200.0M-$150.0M-$100.0M-$50.0M02016: -$85.7M-$85.7M20162017: -$110.0M-$110.0M2017+28%2018: -$126.8M-$126.8M2018+15%2019: -$119.0M-$119.0M2019−6%2020: -$119.7M-$119.7M2020+1%2021: -$150.4M-$150.4M2021+26%2022: -$70.0M-$70.0M2022−53%
Net income56784-$103.4M in 2022+18% since 2016
-$200.0M-$150.0M-$100.0M-$50.0M02016: -$87.7M-$87.7M20162017: -$131.2M-$131.2M2017+50%2018: -$117.4M-$117.4M2018−10%2019: -$123.7M-$123.7M2019+5%2020: -$146.2M-$146.2M2020+18%2021: -$199.8M-$199.8M2021+37%2022: -$103.4M-$103.4M2022−48%
Fiscal year2016201720182019202020212022
Revenue$20.6M5$38.0M6$89.1M7$101.2M8$144.4M8$95.4M4$102.8M4
Cost of revenue$19.7M5$25.1M6$47.0M7$69.6M8$95.4M8$62.9M4$76.1M4
Gross profit$42.1M7$31.6M8$49.0M8$32.5M4$26.7M4
Research and development$60.6M5$76.8M6$119.9M7$84.4M8$75.9M8$77.7M4$51.8M4
Selling, general and admin$26.0M5$46.1M6$49.0M7$66.3M8$92.9M8$64.2M4$44.9M4
Operating expenses$182.9M4$96.7M4
Operating income-$85.7M5-$110.0M6-$126.8M7-$119.0M8-$119.7M8-$150.4M4-$70.0M4
Interest$1.9M11$6.3M6$3.6M7$7.0M8$11.2M8$20.7M4$25.8M4
Income before tax-$171.0M4-$98.6M4
Income tax-$265.0K5$85.0K6$100.0K7$928.0K8$4.1M8-$10.6M4$347.0K4
Net income-$87.7M5-$131.2M6-$117.4M7-$123.7M8-$146.2M8-$199.8M4-$103.4M4
Earnings per share-$38.444-$15.814
Earnings per share (diluted)-$38.444-$15.814
Shares (weighted, basic)5.2M shares46.5M shares4
Shares (weighted, diluted)5.2M shares46.5M shares4

Compare Athenex, Inc. with another company

Corporate structure

Athenex, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Athenex, Inc.

  • Athenex, Inc. Buffalo, New York, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Athenex, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Machinery and equipment$2.7M4 Dec 31, 2022$2.6M4 Dec 31, 2021+1.9%
Furniture and fixtures$75.0K4 Dec 31, 2022$223.0K4 Dec 31, 2021−66.4%
Computer equipment and software$2.6M4 Dec 31, 2022$3.7M4 Dec 31, 2021−30.3%
Leasehold improvements$690.0K4 Dec 31, 2022$1.2M4 Dec 31, 2021−42.1%
Construction in progress$238.0K4 Dec 31, 2022$147.0K4 Dec 31, 2021+61.9%
Property and equipment, before depreciation$6.3M4 Dec 31, 2022$7.9M4 Dec 31, 2021−20.7%
Accumulated depreciation$4.5M4 Dec 31, 2022$4.7M4 Dec 31, 2021−5.7%
Property and equipment, net$1.8M4 Dec 31, 2022$3.2M4 Dec 31, 2021−42.8%
Finance-lease assets$200.0K4 Dec 31, 2022$315.0K4 Dec 31, 2021−36.5%
Operating-lease assets (leased space)$4.2M4 Dec 31, 2022$5.7M4 Dec 31, 2021−25.6%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$30.4M4 Dec 31, 2022$35.2M4 Dec 31, 2021−13.5%
Marketable securities, current$1.1M4 Dec 31, 2022$10.2M4 Dec 31, 2021−89.5%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$04 Dec 31, 2022$04 Dec 31, 2021
Intangible assets, net (excluding goodwill)$72.1M4 Dec 31, 2022$71.9M4 Dec 31, 2021+0.3%
Accumulated amortization$7.6M4 Dec 31, 2022$9.9M4 Dec 31, 2021−23.4%
Finite-lived intangibles, net$6.6M4 Dec 31, 2022$6.3M8 Dec 31, 2021+4.7%

Inventory

ItemLatestA year beforeChange
Inventory, total$42.7M4 Dec 31, 2022$23.1M4 Dec 31, 2021+84.9%
Work in process$69.0K4 Dec 31, 2022$12.0K4 Dec 31, 2021+475.0%
Finished goods$36.9M4 Dec 31, 2022$20.1M4 Dec 31, 2021+83.5%

Leadership

Who has led Athenex, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Johnson Yiu Nam Lau2017–2023

Chair

  1. Johnson Yiu Nam Lau2017–2023

President

  1. William Wei Zuo2017–2021

Chief financial officer

  1. J. Nick Riehle2017
  2. Randoll Sze2018–2020
  3. Joe Annoni2022–2023
20202025
Board members and other officers (24)

Former names

  • Kinex Pharmaceuticals, Inc.Dec 23, 2013 to Jun 16, 20153
  • Kinex Pharmaceuticals LLCAug 13, 2004 to Aug 6, 20123

Timeline

  1. Oct 2, 20238-K Bankruptcy or receivership; Completed an acquisition or sale; Change to shareholders' rights39
  2. Aug 17, 20238-K Executive or director change40
  3. Jul 18, 20238-K Entered a material agreement; Ended a material agreement; Bankruptcy or receivership41
  4. May 22, 20238-K Bankruptcy or receivership; Debt or obligation accelerated; Exit or restructuring costs42
  5. May 3, 20238-K Listing notice or transfer43
  6. Apr 25, 20238-K Executive or director change44
  7. Mar 31, 20238-K Bylaws or fiscal year changed45
  8. Mar 20, 20238-K Results of operations46
  9. Feb 14, 20238-K Change to shareholders' rights; Bylaws or fiscal year changed; Other events47
  10. Nov 22, 20228-K Executive or director change; Bylaws or fiscal year changed; Shareholder vote48
  11. Nov 21, 20228-K Entered a material agreement; Completed an acquisition or sale49
  12. Nov 3, 20228-K Results of operations; Regulation FD disclosure50
  13. Jun 21, 2017New chief executive Johnson Yiu Nam Lau becomes CEO12
  14. Nov 4, 2003Founded Athenex, Inc. is founded2

Calendar

When it reported results

  1. Mar 20, 2023Reported quarterly or annual results46
  2. Nov 3, 2022Reported quarterly or annual results50
  3. Jul 28, 2022Reported quarterly or annual results51
  4. May 10, 2022Reported quarterly or annual results52
  5. Mar 16, 2022Reported quarterly or annual results53
  6. Nov 4, 2021Reported quarterly or annual results54

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

222 filings to the SEC since October 2021: 3 annual reports, 4 quarterly reports, 33 major events, 161 insider forms, 7 large holders, 14 other. The latest 20:

  1. Oct 18, 2023SC 13D/A EDGAR
  2. Oct 2, 20238-K EDGAR
  3. Aug 17, 20238-K EDGAR
  4. Jul 18, 20238-K EDGAR
  5. Jul 10, 202325-NSE EDGAR
  6. May 23, 2023NT 10-Q EDGAR
  7. May 22, 20238-K EDGAR
  8. May 8, 20234 FORM 4 SUBMISSION EDGAR
  9. May 8, 20234 FORM 4 SUBMISSION EDGAR
  10. May 8, 20234 FORM 4 SUBMISSION EDGAR
  11. May 3, 20238-K EDGAR
  12. Apr 28, 202310-K/A EDGAR
  13. Apr 25, 20238-K EDGAR
  14. Apr 24, 20234 FORM 4 SUBMISSION EDGAR
  15. Apr 24, 20234 FORM 4 SUBMISSION EDGAR
  16. Apr 24, 20234 FORM 4 SUBMISSION EDGAR
  17. Apr 24, 20234 FORM 4 SUBMISSION EDGAR
  18. Apr 24, 20234 FORM 4 SUBMISSION EDGAR
  19. Apr 24, 20234 FORM 4 SUBMISSION EDGAR
  20. Apr 24, 20234 FORM 4 SUBMISSION EDGAR

The 222 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

11 open-market trades by officers, directors and large owners since October 2021: 11 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 22, 2022WU JINNDirectorBuy10,000$0.42$4.2KForm 4
Aug 19, 2022LAU JOHNSON YIU NAMCEO and Chairman of the BoardBuy20,000$0.45$9.0KForm 4
Nov 22, 2021LAU JOHNSON YIU NAMCEO and Chairman of the BoardBuy3,000$1.84$5.5KForm 4
Nov 18, 2021LAU JOHNSON YIU NAMCEO and Chairman of the BoardBuy3,000$1.87$5.6KForm 4
Nov 17, 2021Kanfer JordanDirectorBuy4,952$2.02$10.0KForm 4
Nov 17, 2021WU JINNDirectorBuy30,000$2.03$60.9KForm 4
Nov 16, 2021Kwan RudolfEVP, Chief Medical OfficerBuy4,000$2.05$8.2KForm 4
Nov 16, 2021LAU JOHNSON YIU NAMCEO and Chairman of the BoardBuy3,000$2.06$6.2KForm 4
Nov 15, 2021LAU JOHNSON YIU NAMCEO and Chairman of the BoardBuy5,000$2.12$10.6KForm 4
Nov 12, 2021LAU JOHNSON YIU NAMCEO and Chairman of the BoardBuy10,000$2.07$20.7KForm 4
Oct 1, 2021WU JINNDirectorBuy10,000$2.67$26.7KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Athenex, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAthenex, Inc.1
  • CIK0001300699
  • Employer ID (EIN)43-19859661
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • Business address1001 Main Street, Suite 600, Buffalo, NY 142031
  • Phone716-898-86251
  • Shares outstanding8,663,209 as of Mar 13, 202359
  • Public float$32.5M as of Jun 30, 202259
  • On EDGAR sinceAug 13, 20041
  • Filings708 in all: 4 (393), 8-K (96), 4/A (32), 3 (30), 10-Q (17), SC 13G/A (12), D (11), CORRESP (10)1
    All 42 form types

    CT ORDER (8), SC 13G (8), UPLOAD (8), 10-K (6), 424B5 (6), DEF 14A (6), REGDEX (6), REGDEX/A (5), SC 13D/A (5), EFFECT (4), S-3ASR (4), S-8 (4), 3/A (3), DEFA14A (3), S-1/A (3), SC 13D (3), 424B4 (2), D/A (2), DRS (2), DRS/A (2), DRSLTR (2), PRE 14A (2), S-1 (2), 10-K/A (1), 25-NSE (1), 8-A12B (1), 8-K/A (1), CERTNAS (1), NT 10-Q (1), POS AM (1), POS EX (1), POSASR (1), S-3 (1), S-3/A (1)

  • Latest filingsAnnual report (10-K) Mar 20, 2023
    Quarterly report (10-Q) Nov 3, 2022
    Proxy statement (DEF 14A) Oct 11, 2022
    Latest 8-K (8-K) Oct 2, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60